| Literature DB >> 34952604 |
Ayodamola Otun1, Diego M Morales2, Maria Garcia-Bonilla2, Seth Goldberg3, Leandro Castaneyra-Ruiz4, Yan Yan5, Albert M Isaacs6, Jennifer M Strahle2, James P McAllister2, David D Limbrick2.
Abstract
BACKGROUND: Intraventricular hemorrhage (IVH) and post-hemorrhagic hydrocephalus (PHH) have a complex pathophysiology involving inflammatory response, ventricular zone and cell-cell junction disruption, and choroid-plexus (ChP) hypersecretion. Increased cerebrospinal fluid (CSF) cytokines, extracellular matrix proteins, and blood metabolites have been noted in IVH/PHH, but osmolality and electrolyte disturbances have not been evaluated in human infants with these conditions. We hypothesized that CSF total protein, osmolality, electrolytes, and immune cells increase in PHH.Entities:
Keywords: CSF electrolytes; CSF osmolality; Cerebrospinal fluid (CSF); Intraventricular hemorrhage (IVH); Post-hemorrhagic hydrocephalus (PHH)
Mesh:
Year: 2021 PMID: 34952604 PMCID: PMC8710025 DOI: 10.1186/s12987-021-00295-8
Source DB: PubMed Journal: Fluids Barriers CNS ISSN: 2045-8118
Summary of patient characteristics
| Control (N = 18) | LGIVH (N = 10) | HGIVH (N = 13) | PHH (N = 11) | P value | |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 13 (72.2) | 6 (60.0) | 12 (92.3) | 9 (81.8) | |
| Female | 5 (27.8) | 4 (40.0) | 1 (7.7) | 2 (18.2) | |
| PMA birth (weeks) | 31.1 ± 2.9 | 28.2 ± 2.8 | 26.2 ± 2.7 | 27.6 ± 3.1 | 0.0009 control vs HGIVH (0.0005) |
| Birth Weight (g) | 1388.0 ± 395.5 | 1453.0 ± 752.8 | 986.2 ± 396.2 | 1041.1 ± 260.9 | 0.037 control vs HGIVH (0.032) |
| CRIB II—T Score | 4.6 ± 4.5 | 6.9 ± 4.7 | 10.7 ± 3.9 | 8.7 ± 4.2 | 0.012 control vs HGIVH (0.0076) |
| Complex Chronic Conditions | 0.8 ± 0.8 | 1.0 ± 0.7 | 0.8 ± 1.2 | 1.4 ± 1.1 | 0.39 |
| None | 9 (50.0) | 2 (20.0) | 7 (53.8) | 3 (27.3) | |
| 1–2 | 9 (50.0) | 8 (80.0) | 5 (38.5) | 6 (54.5) | |
| 3–4 | 0 | 0 | 1 (7.7) | 2 (18.2) | |
| > 4 | 0 | 0 | 0 | 0 | |
| Respiratory | 6 | 4 (40.0) | 4 (30.8) | 7 (63.6) | |
| Cardiovascular | 3 (16.7) | 0 | 2 (15.4) | 4 (36.4) | |
| Neuromuscular | 2 (11.1) | 0 | 0 | 0 | |
| Ophthalmologic | 1 (5.6) | 1 (10.0) | 1 (7.7) | 0 | |
| Gastrointestinal | 0 | 0 | 2 (15.4) | 1 (9.1) | |
| Infectious | 0 | 3 (30.0) | 0 | 0 | |
| Hematologic | 1 (5.6) | 0 | 0 | 0 | |
| NAS | 1 (5.6) | 2 (20.0) | 0 | 0 | |
| FOR measurement | 0.35 ± 0.04 | 0.41 ± 0.07 | 0.49 ± 0.06 | 0.65 ± 0.03 | < 0.0001 Control vs HGIVH (0.0003) and PHH (< 0.0001); LGIVH vs HGIVH (0.034) and PHH (< 0.0001); HGIVH vs PHH (< 0.0001) |
Values are reported as N (column %) or mean ± standard deviation. In the “P value’ column, ANOVA summary p-value was recorded on the top row while significant pairwise post-test P value were recorded on the bottom row. All pairwise comparisons were analyzed based on Dunn’s or Tukey’s post-test ANOVA depending on the distribution of the data (normal distribution or not). N, sample size; PMA, post-menstrual age; NAS, neonatal abstinence syndrome; FOR, frontal-occipital horn ratio
Serum and CSF cellularity
| Control (N = 18) | LGIVH (N = 10) | HGIVH (N = 13) | PHH (N = 11) | P value | |
|---|---|---|---|---|---|
| CSF | |||||
| Total cells (cells/mcl) | 1711 ± 4305 | 452.7 ± 596.1 | 12,572 ± 24,771 | 39,788 ± 70,835 | 0.014 Control vs PHH (0.012) |
| Nucleated cells (cells/mcl) | 3.8 ± 4.2 | 2.8 ± 3.2 | 67.2 ± 95.4 | 287.7 ± 433.2 | Control vs HGIVH (0.0079) and PHH (0.0005); LGIVH vs HGIVH (0.011) and PHH (0.0010) |
| Lymphocytes (%) | 25.7 ± 16.3 | 23.0 ± 17.9 | 10.4 ± 4.5 | 17.1 ± 11.6 | 0.051 Control vs HGIVH (0.043) |
| Neutrophils (%) | 25.0 ± 11.7 | 30.0 ± 30.3 | 38.2 ± 32.4 | 49.4 ± 28.7 | 0.24 |
| Monocytes (%) | 48.7 ± 22.9 | 46.6 ± 34.2 | 39.6 ± 32.6 | 16.3 ± 10.7 | 0.024 Control vs PHH (0.016) |
| Macrophages (%) | 10.2 ± 9.2 | 29.0 ± 25.2 | 28.3 ± 38.2 | 10.2 ± 6.1 | 0.23 |
| Serum | |||||
| WBC (K/cumm) | 12.1 ± 6.6 | 14.8 ± 9.9 | 15.0 ± 10.0 | 22.9 ± 10.0 | 0.051 |
| Control vs PHH (0.042) | |||||
| RBC (K/cumm) | 3.5 ± 0.7 | 3.7 ± 0.9 | 3.2 ± 0.6 | 3.5 ± 0.4 | 0.34 |
| Platelet (K/cumm) | 329.6 ± 134.9 | 223.0 ± 66.6 | 202.9 ± 104.5 | 251.5 ± 92.2 | 0.032 Control vs HGIVH (0.030) |
| Neutrophils (%) | 47.5 ± 21.7 | 46.1 ± 25.1 | 42.2 ± 21.9 | 55.0 ± 13.4 | 0.53 |
| Lymphocytes (%) | 40.7 ± 20.0 | 31.9 ± 18.6 | 36.5 ± 17.7 | 27.9 ± 11.8 | 0.37 |
| Monocytes (%) | 8.3 ± 4.2 | 11.3 ± 4.5 | 9.5 ± 5.9 | 12.0 ± 5.4 | 0.18 |
Values are reported as N (column %) or mean ± standard deviation. In the “P value’ column, ANOVA summary p-value was recorded on the top row while significant pairwise post-test P value were recorded on the bottom row. All pairwise comparisons were analyzed based on Dunn’s or Tukey’s post-test ANOVA depending on the distribution of the data (normal distribution or not). Cell differential reported as % of total WBC. WBC, white blood cells; RBC, red blood cells
Fig. 1CSF and serum osmolality, total protein, and glucose in human infants with PHH. A chart showing increased CSF osmolality in PHH (n = 7) compared to control (n = 12), low grade IVH (n = 7), and high grade IVH (n = 7) (p = 0.0006, < 0.0001, 0.0003 respectively; Tukey’s post-test ANOVA). B chart showing increased total protein concentration in HGIVH (n = 11) and PHH (n = 11) compared to control (n = 16) (p = 0.0009 and 0.0006 respectively Tukey’s post-test ANOVA) and LGIVH (n = 9) (p = 0.034 and 0.028 respectively Tukey’s post-test ANOVA). C chart showing decreased glucose in PHH (n = 5) compared to control (n = 12), LGIVH (n = 7), and HGIVH (n = 7) (p = 0.0002, 0.0047, and 0.041 respectively Tukey’s post-test ANOVA). D chart showing no change in serum calculated osmolality across all the groups (ANOVA summary p-value = 0.71) (n = 19 control, 9 LGIVH, 7 HGIVH, and 11 PHH). E chart showing no change in serum total protein across all the groups (ANOVA summary p-value = 0.11) (n = 5 control, 5 LGIVH, 5 HGIVH, and 4 PHH). F chart showing no change in serum glucose across all the groups (ANOVA summary p-value = 0.37) (n = 12 control, 7 LGIVH, 7 HGIVH, 5 PHH)
Fig. 2Increased Sodium, Potassium, and Chloride only in PHH. A chart showing increased CSF Na+ concentration in PHH (n = 7) compared to control (n = 12), low grade IVH (n = 7), and high grade IVH (n = 7) (p = < 0.0001, 0.0017, 0.0013 respectively; Tukey’s post-test ANOVA). B chart showing increased CSF K+ concentration in PHH (n = 5) compared to control (n = 13), low grade IVH (n = 8), and high grade IVH (n = 7) (p = 0.0002, 0.0023, 0.0037 respectively; Tukey’s post-test ANOVA). C chart showing increased CSF Cl− concentration in PHH (n = 7) compared to control (n = 13), low grade IVH (n = 6), and high grade IVH (n = 7) (p = 0.012, 0.023, 0.015 respectively; Tukey’s post-test ANOVA). D chart showing no change in serum sodium across all the groups (ANOVA summary p-value = 0.89) (n = 13 control, 9 LGIVH, 7 HGIVH, and 11 PHH). E chart showing no change in serum potassium across all the groups (ANOVA summary p-value = 0.57) (n = 13 control, 9 LGIVH, 7 HGIVH, and 11 PHH). F chart showing no change in serum chloride across all the groups (ANOVA summary p-value = 0.30) (n = 13 control, 9 LGIVH, 6 HGIVH, and 11 PHH)
Increased CSF Calcium and Magnesium in PHH but no difference in Bicarbonate compared to Control
| Control | LGIVH | HGIVH | PHH | P value | ||
|---|---|---|---|---|---|---|
| Magnesium | CSF | 2.6 ± 0.6 (n = 13) | 2.5 ± 0.3 (n = 6) | 3.1 ± 0.6 (n = 6) | 3.7 ± 0.8 (n = 4) | 0.024 Control vs PHH (0.031); and LGIVH vs PHH (0.041) |
| Calcium | CSF | 2.9 ± 0.7 (n = 15) | 1.7 ± 0.8 (n = 7) | 3.3 ± 0.9 (n = 7) | 4.3 ± 0.3 (n = 4) | < 0.0001 Control vs LGIVH (0.013) and PHH (0.012); LGIVH vs HGIVH (0.0046) and PHH (< 0.0001) |
| Serum | 9.9 ± 0.5 (n = 9) | 9.5 ± 0.6 (n = 5) | 9.8 ± 0.4 (n = 6) | 10.1 ± 0.3 (n = 5) | 0.21 | |
| Bicarbonate | CSF | 17.3 ± 4.3 (n = 13) | 13.3 ± 2.3 (n = 7) | 19.5 ± 2.3 (n = 6) | 19.8 ± 1.0 (n = 4) | 0.0062 LGIVH vs HGIVH (0.010) and PHH (0.019) |
| Serum | 24.9 ± 4.4 (n = 13) | 25.1 ± 1.6 (n = 8) | 24.3 ± 2.8 (n = 6) | 25.9 ± 4.4 (n = 11) | 0.85 |
Values recorded as mean ± standard deviation. In the “P value’ column, ANOVA summary p-value was recorded on the top row while significant pairwise post-test P value were recorded on the bottom row. All pairwise comparisons were analyzed based on Dunn’s or Tukey’s post-test ANOVA depending on the distribution of the data (normal distribution or not). n, represents sample size
Absolute and Percent change in electrolyte concentrations in PHH compared to Control
| Control (mmol/L) | PHH (mmol/L) | Absolute change (mmol/L) | Percent change (%) | |
|---|---|---|---|---|
| Total protein | 5.3 | 11.2 | 5.9 | 111.3 |
| Glucose | 2.9 | 1.3 | − 1.6 | -55.2 |
| Sodium | 142.3 | 179.9 | 37.6 | 26.4 |
| Potassium | 3.1 | 4.1 | 1 | 32.3 |
| Chloride | 122.4 | 143.3 | 20.9 | 17.1 |
| Bicarbonate | 17.3 | 19.8 | 2.5 | 14.5 |
| Calcium | 0.16 | 0.24 | 0.08 | 50.0 |
| Magnesium | 0.14 | 0.21 | 0.07 | 50.0 |
| Calculated Total Osmoles | 296.2 | 364.1 | 67.9 | |
| Measured Osmolality | 280.8 | 336.5 | 55.7 | 19.8 |
| Unaccounted Osmoles | 15.4 | 27.6 | 12.2 |
Absolute change is the difference in concentration between the Control and PHH values. Percent change is the difference divided by the control value and multiplied by 100. Calculated total osmoles is the sum of the electrolytes, total protein, and glucose in each group (control or PHH). Measured osmolality is the mean osmolality obtained from actual measurement with VAPRO osmometer. Unaccounted osmoles represent the difference in the calculated total osmoles and the measured osmolality